The same authors noted that NOTCH1M plus lower BAX/BCL-2 ratio identified a CLL subset showing the worst PFS and OS, emphasizing the likelihood of either new small-molecule combination approaches or antibodies targeting NOTCH1 being more appropriate therapeutic options for NOTCH1-mutated patients [28]. The gene discussed is BAX; the disease is B-cell chronic lymphocytic leukemia.